glp-1 receptor agonist common side effects glp 1 long term Overdose risks increase as demand for injectable weight-loss drugs on the rise, research finds Table 2 from Optimizing Outcomes
Description
BMC Endocr Disord 2010;10:7
These figures represent a substantial growth: 33-40% since 2018, a stark contrast to the more modest increases of 7-10% seen in the previous five years
Pfizer will still need to do large scale clinical trials to produce the data necessary to show its safe, effective and tolerable and then submit to FDA -- a process which is still likely much further down the line.
Fernndez Land, K
Many pharmaceutical companies lack internal peptide manufacturing at commercial scale
Which treatment participants get is randomized
